someone in need
10-28-2005, 03:12 PM
http://www.bnl.gov/bnlweb/pubaf/pr/PR_display.asp?prID=05-49
Two Studies Offer Clues About How Alcoholic Behavior is “Switched” On
Papers describe how efforts to block or modify reward circuits affect
drinking in animals
May 9, 2005
UPTON, NY - As part of an ongoing effort to understand the biochemical
basis of alcohol abuse, scientists at the U.S. Department of Energy’s
Brookhaven National Laboratory have published two studies on how
modulating receptors for dopamine — a chemical “signaler” in the
brain’s reward circuits — affects drinking behavior in mice and rats.
Photo of Peter Thanos
“Stopping alcohol abuse will never be as simple as turning on or off a
‘switch,’ but finding ways to modulate the brain’s reward circuits
could play a role in developing successful treatments,” said
Brookhaven’s Panayotis (Peter) Thanos, lead author of both studies.
The studies appear in the May 27, 2005, issue of Life Sciences and the
June 2005 issue of Pharmacology Biochemistry and Behavior, both now
available online.
In the first study, the scientists increased the number of dopamine
“D2” receptors in strains of mice with genetically varying levels of
D2 receptors. Earlier Brookhaven studies have shown that
“up-regulating” D2 receptors by delivering the D2 gene directly to the
brain’s reward center decreased drinking behavior in rats trained or
genetically predisposed to drink large quantities of alcohol.
The Life Sciences study demonstrates this same “alcoholism-quenching”
effect of D2 “gene therapy” in mice with normal to moderately low
levels of D2s, supporting the idea that receptor up-regulation could
play a role in the treatment of alcoholism.
Also in that study, however, so-called “knockout” mice, which
initially had no D2s, drank more in response to D2 up-regulation.
“This suggests that there may be a threshold level of D2 receptors
needed for animals to respond to the reinforcing effects of alcohol,”
Thanos said.
“When we up-regulated D2 levels in the knockout mice, we may have
approached or obtained D2 levels close to this threshold, thus
producing the reinforcement and an increase in ethanol intake,” Thanos
said. But, he added, this doesn’t mean that D2 up-regulation would
turn non-drinkers into alcoholics. “We could speculate that further
increases in D2, above this threshold, would result in a decrease in
ethanol consumption in this group as well,” he said.
In the second study, Thanos’ group tested the idea that blocking the
activity of another kind of dopamine receptor, known as D3, might
reduce alcohol consumption. They tested their hypothesis in rats with
a genetic predisposition to prefer alcohol when given a choice between
a 10 percent ethanol solution and pure water, comparing them with rats
that had no prior preference for alcohol. Both sets of animals were
treated with varying doses of “SB-277011-A,” a known D3 receptor
“antagonist” — a chemical that binds to the receptor thus blocking
dopamine’s ability to bind and send its pleasure/reward signal.
The two higher doses of the antagonist (10 and 30 milligrams per
kilogram body weight) reduced drinking behavior in the
alcohol-preferring rats; the highest dose decreased drinking (though
less dramatically) in the non-preferring group, which drank less to
begin with. The lowest dose (3mg/kg) had no effect in either group.
None of the doses caused any side effects.
“Recent studies have demonstrated that SB-277011-A is a highly
selective D3-blocker and also reduces cocaine-seeking behavior, as
well as behavior involving other drugs of abuse, such as nicotine and
heroin,” Thanos said.
While it is well known that brain circuits modulated by other
neurotransmitters (such as glutamate and serotonin) also play a role
in alcohol intake, Thanos said, “these two studies provide further
insight into the complex roles of dopamine — and may help us better
understand the mechanism(s) of alcohol abuse and assist in the
development of specific, molecular-based treatments.”
The Life Sciences study was funded by the Office of Biological and
Environmental Research (OBER) with the U.S. Department of Energy's
Office of Science and by the National Institute on Alcohol Abuse and
Alcoholism (NIAAA), the National Institute on Mental Health, and the
National Institute on Drug Abuse (NIDA). Collaborators at Oregon
Health and Science University, the University of Buenos Aires, and the
University of Nagoya School of Medicine are co-authors on this paper.
The Pharmacology, Biochemistry and Behavior study was funded by DOE's
OBER and NIAAA. Researchers at St. John's University, NIDA,
GlaxoSmithKline Pharmaceuticals, and NIAAA collaborated on this study.
DOE has a long-standing interest in research on addiction that builds,
as this study does, on the knowledge of brain receptors gained through
brain-imaging studies. Brain-imaging techniques such as MRI and PET
are a direct outgrowth of DOE's support of basic physics research.
Two Studies Offer Clues About How Alcoholic Behavior is “Switched” On
Papers describe how efforts to block or modify reward circuits affect
drinking in animals
May 9, 2005
UPTON, NY - As part of an ongoing effort to understand the biochemical
basis of alcohol abuse, scientists at the U.S. Department of Energy’s
Brookhaven National Laboratory have published two studies on how
modulating receptors for dopamine — a chemical “signaler” in the
brain’s reward circuits — affects drinking behavior in mice and rats.
Photo of Peter Thanos
“Stopping alcohol abuse will never be as simple as turning on or off a
‘switch,’ but finding ways to modulate the brain’s reward circuits
could play a role in developing successful treatments,” said
Brookhaven’s Panayotis (Peter) Thanos, lead author of both studies.
The studies appear in the May 27, 2005, issue of Life Sciences and the
June 2005 issue of Pharmacology Biochemistry and Behavior, both now
available online.
In the first study, the scientists increased the number of dopamine
“D2” receptors in strains of mice with genetically varying levels of
D2 receptors. Earlier Brookhaven studies have shown that
“up-regulating” D2 receptors by delivering the D2 gene directly to the
brain’s reward center decreased drinking behavior in rats trained or
genetically predisposed to drink large quantities of alcohol.
The Life Sciences study demonstrates this same “alcoholism-quenching”
effect of D2 “gene therapy” in mice with normal to moderately low
levels of D2s, supporting the idea that receptor up-regulation could
play a role in the treatment of alcoholism.
Also in that study, however, so-called “knockout” mice, which
initially had no D2s, drank more in response to D2 up-regulation.
“This suggests that there may be a threshold level of D2 receptors
needed for animals to respond to the reinforcing effects of alcohol,”
Thanos said.
“When we up-regulated D2 levels in the knockout mice, we may have
approached or obtained D2 levels close to this threshold, thus
producing the reinforcement and an increase in ethanol intake,” Thanos
said. But, he added, this doesn’t mean that D2 up-regulation would
turn non-drinkers into alcoholics. “We could speculate that further
increases in D2, above this threshold, would result in a decrease in
ethanol consumption in this group as well,” he said.
In the second study, Thanos’ group tested the idea that blocking the
activity of another kind of dopamine receptor, known as D3, might
reduce alcohol consumption. They tested their hypothesis in rats with
a genetic predisposition to prefer alcohol when given a choice between
a 10 percent ethanol solution and pure water, comparing them with rats
that had no prior preference for alcohol. Both sets of animals were
treated with varying doses of “SB-277011-A,” a known D3 receptor
“antagonist” — a chemical that binds to the receptor thus blocking
dopamine’s ability to bind and send its pleasure/reward signal.
The two higher doses of the antagonist (10 and 30 milligrams per
kilogram body weight) reduced drinking behavior in the
alcohol-preferring rats; the highest dose decreased drinking (though
less dramatically) in the non-preferring group, which drank less to
begin with. The lowest dose (3mg/kg) had no effect in either group.
None of the doses caused any side effects.
“Recent studies have demonstrated that SB-277011-A is a highly
selective D3-blocker and also reduces cocaine-seeking behavior, as
well as behavior involving other drugs of abuse, such as nicotine and
heroin,” Thanos said.
While it is well known that brain circuits modulated by other
neurotransmitters (such as glutamate and serotonin) also play a role
in alcohol intake, Thanos said, “these two studies provide further
insight into the complex roles of dopamine — and may help us better
understand the mechanism(s) of alcohol abuse and assist in the
development of specific, molecular-based treatments.”
The Life Sciences study was funded by the Office of Biological and
Environmental Research (OBER) with the U.S. Department of Energy's
Office of Science and by the National Institute on Alcohol Abuse and
Alcoholism (NIAAA), the National Institute on Mental Health, and the
National Institute on Drug Abuse (NIDA). Collaborators at Oregon
Health and Science University, the University of Buenos Aires, and the
University of Nagoya School of Medicine are co-authors on this paper.
The Pharmacology, Biochemistry and Behavior study was funded by DOE's
OBER and NIAAA. Researchers at St. John's University, NIDA,
GlaxoSmithKline Pharmaceuticals, and NIAAA collaborated on this study.
DOE has a long-standing interest in research on addiction that builds,
as this study does, on the knowledge of brain receptors gained through
brain-imaging studies. Brain-imaging techniques such as MRI and PET
are a direct outgrowth of DOE's support of basic physics research.